AE Management of IO/TKI and Future of nccRCC

Opinion
Video

Medical experts discuss significant adverse effects of TKIs and IOs, including management and patient education, and highlight exciting pipeline therapies for non–clear cell RCC, such as Ipi + Nivo and zanzalintinib + Nivo.

Video content above is prompted by the following:

  • What are the most significant adverse effects seen with TKIs and IOs?
    • How do you manage, monitor, and mitigate AEs seen with TKIs/IOS?

What education do you provide patients to ensure they understand their recommended treatment regimens and potential adverse effects with of these frontline agents?

  • What pipeline therapies are you most excited about for the treatment of nccRCC?
Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series
3 KOLs are featured in this series.
4 KOLs are featured in this series
4 KOLs are featured in this series
Related Content